KR20210017293A - COMPOSITION FOR PREVENTION AND TREATMENT OF Hepatic Fibrosis CONTAINING LYSIMACHIA VULGARIS EXTRACT - Google Patents

Abstract

The present invention relates to a pharmaceutical composition or a food composition for preventing or treating steatohepatitis, containing a Lysimachia vulgaris extract as an active component, which provides a composition for reducing hepatic fibrosis caused by steatohepatitis. The composition of the present invention has no side effects and has excellent stability even when applied to a living body by containing a natural extract, the Lysimachia vulgaris extract, as the active component.

Description

A composition for the prevention and treatment of liver fibrosis, comprising the extract of eyelets as an active ingredient {COMPOSITION FOR PREVENTION AND TREATMENT OF Hepatic Fibrosis CONTAINING LYSIMACHIA VULGARIS EXTRACT}

The present invention relates to a composition for preventing and treating liver fibrosis comprising an extract of Lysimachia vulgaris var. davurica as an active ingredient.

With the recent economic growth and the improvement of living standards, the incidence of various diseases due to the increase in the intake of saturated animal fat is increasing as the dietary life changes in a westernized pattern. In particular, the incidence of vascular circulatory diseases such as arteriosclerosis, high blood pressure and heart disease is on the rise, and such vascular circulatory diseases include large intakes of triglycerides and cholesterol, genetic factors, obesity, excessive intake of calories, lack of exercise, alcohol consumption. It is known that it is caused by an increase in the concentration of cholesterol and triglycerides in the blood by smoking, etc.

Recently, the term'metaflammation' has recently emerged for inflammatory reactions caused by an oversupply of nutrients or metabolites, and obesity is referred to as'chronic and low-level inflammation'. Research on the relationship between obesity and the immune system, such as interpretation, is actively underway. In addition, obesity is caused by storing triglycerides in the cytoplasm of differentiated adipocytes through a series of processes including the aggregation of adipocyte precursors and differentiation of new adipocytes.

In addition, non-alcoholic fatty liver disease (NAFLD) induced by obesity refers to a disease in a broad sense including fatty liver or simple fatty liver with inflammation in the liver, steatohepatitis, liver fibrosis, cirrhosis, etc., regardless of alcohol consumption. It is highly associated with hyperlipidemia, type 2 diabetes, and insulin resistance, so it can be seen as a sign of metabolic disease. Therefore, it is reported that monotherapy alone is insufficient for the treatment of NAFLD, and a combination therapy of therapeutic agents capable of treating various metabolic diseases is required.

Since the millet has various pharmacological activities, antibacterial, anti-inflammatory, and anticancer activities have been reported in the academic world. However, there has been no reported efficacy in preventing liver fibrosis. Under this technical background, research on the millet is being actively conducted (Registration Patent 16-277040000), but it is still insufficient.

In the present invention, it was found that the millet extract has excellent efficacy in a steatohepatitis model, and the present invention was completed by confirming that it can be usefully used as a composition for the prevention and treatment of steatohepatitis.

The present invention is to provide a composition for the prevention and treatment of liver fibrosis comprising the extract as an active ingredient. In addition, the present invention is to provide a food composition for preventing or improving liver fibrosis, comprising the extract of eyelets as an active ingredient.

Each description and embodiment disclosed in the present application can be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present application belong to the scope of the present application. In addition, it cannot be considered that the scope of the present application is limited by the specific description described below.

One aspect provides a pharmaceutical composition for the prevention or treatment of liver fibrosis, comprising an extract of millet algae as an active ingredient.

In the present specification, the term "prevention" may refer to any action that suppresses steatohepatitis or delays the onset of the disease by administration of the pharmaceutical composition according to an embodiment.

As used herein, the term "treatment" refers to any action in which symptoms for steatohepatitis are improved or beneficially altered by administration of the pharmaceutical composition according to an embodiment, and of a disease, disorder or condition, or one or more symptoms thereof. It may refer to, or include alleviation, inhibition or prevention of progression.

In the present specification, the terms, "disorder" and "disease" may be understood to have the same meaning.

In the present specification, "active ingredient" refers to an ingredient that can exhibit a desired activity by itself or, together with a carrier that is not itself active, to exhibit a desired activity.

In the present specification, the millet is English name Yellow Loosestrife, scientific name Lysimachia vulgaris var. As a plant having davurica, the herbal name is also called Coptis Rhizoma. The millet is a perennial herb, with the root diameter extending to the side, the stem grows straight, the height is about 40~80 cm, and the upper part has fine hairs. Leaves are narrow ovate or lanceolate, facing each other, or turning 3~4 each, and the tip and the bottom of the leaves are sharp or slightly blunt. The flower is conical, blooms yellow in July-August, and fruit is fruiting in August-September.

There is no restriction on the method of obtaining the millet, and it can be grown and used or purchased and used. In addition, the millet used in the present specification may use some or all of the above-ground or underground portions of millet. In the exemplary embodiment of the present specification, the above-ground part (leaves, twigs, stems, etc.) and the underground part (roots, seeds, etc.) of the millet are used, but are not limited thereto. In addition, in the present specification, the millet can be used without limitation in the growth stage of the plant.

In the present specification, "for the prevention or treatment of liver fibrosis" includes all of the use of inhibiting the activity of a factor causing liver fibrosis and preventing complications of liver fibrosis, or treating the same.

As used herein, the term "steatohepatitis" is one of the complications of fatty liver, and about 10% of all fatty liver patients are known as steatohepatitis. In most cases, simple fatty liver does not progress to cirrhosis or liver cancer, but when observed for a long period of time, fatty hepatitis progresses to liver cirrhosis in 10-20%. The mechanism of progression from fatty liver to steatohepatitis is not yet clearly identified, but it is known that fat accumulated in the liver secretes substances that cause destruction and inflammation of hepatocytes.

The steatohepatitis may be a non-alcoholic steatohepatitis. Fatty hepatitis can be divided into non-alcoholic steatohepatitis and alcoholic steatohepatitis according to its cause. Alcoholic steatohepatitis is a disease that occurs when the liver promotes fat synthesis and normal energy metabolism does not occur when alcohol is consumed, and non-alcoholic steatohepatitis is observed in patients who do not drink a lot of alcohol.

As used herein, the term "liver cirrhosis" means that due to chronic inflammation, normal liver tissue is transformed into fibrotic tissue such as regenerative nodules (a phenomenon in which small lumps are formed), resulting in decreased liver function.

As used herein, the term "liver fibrosis" refers to a condition in which liver fibers are increased as a result of a liver disorder. As with fibrosis, it is cirrhosis that leads to nodule formation accompanied by remodeling of the lobular structure. In addition to cirrhosis, in heart failure, mainly lobular center line, and in biliary obstruction or idiopathic portal hypertrophy (Banti syndrome), liver fibrosis can be seen around the portal area, and it does not necessarily involve remodeling of the lobular structure.

Another aspect provides a composition for reducing the inflammatory response in liver cells, the active ingredient. In addition, the active ingredient provides a composition for reducing liver damage caused by liver fibrosis. The liver damage includes, for example, steatohepatitis, hepatitis, cirrhosis, hepatic congestion, hemorrhage, and hepatic necrosis, but is not limited thereto.

In the composition of one aspect of the invention, the composition may contain 0.001% to 80% of the millet extract based on the total weight of the composition.

If the composition of one aspect of the present invention contains less than 0.001% of the millet extract, the effect of preventing steatohepatitis is insignificant, and if it contains more than 80%, it affects other compositions and is not appropriate. In view of the above, the composition comprises 0.005 to 78% by weight, 0.01 to 76% by weight, 0.05 to 74% by weight, 0.1 to 72% by weight, 0.5 to 70% by weight, 1 to 68% by weight of the millet extract based on the total weight of the composition. It may be included in wt% or 5 to 66 wt%.

In the present specification, "eyeweed extract" may be a crude extract of a solvent selected from the group consisting of water, C ₁ -C ₆ alcohol, and combinations thereof. The C ₁ -C ₆ alcohol may be specifically methanol or ethanol. The method of preparing the extract is a method using an extraction device such as supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction, or ultrasonic extraction, or a method using an adsorption resin including XAD and HP-20. Method can be used. Specifically, it may be heated and extracted at reflux or at room temperature, but is not limited thereto. In addition, the number of extractions may be 1 to 5 times, but specifically, extraction may be repeated 3 times, but is not limited thereto. The extraction time may be 2 to 12 hours, specifically 3 to 5 hours, but is not limited thereto. In addition, after the extraction, a method such as concentration or freeze-drying may be additionally performed.

Specifically, water, anhydrous or water-containing lower alcohol having 1 to 6 carbon atoms (methanol, ethanol, propanol or butanol), propylene glycol, butylene glycol, dipropylene glycol, glycerin, acetone, ethyl acetate, chloroform, methylene chloride, butyl acetate , Diethyl ether, dichloromethane, and solvent extraction using one or more extraction solvents selected from the group containing hexane, or high-temperature extraction or high pressure extraction or supercritical extraction or subcritical extraction or ultrasonic extraction, or adsorption including XAD and HP-20 It can be extracted using an extraction method using resin, fermentation using microorganisms, or natural fermentation metabolism. In the case of the extraction solvent, it is not limited to the solvents listed above, and the extraction process may be heated and extracted at reflux or at room temperature, but is not limited thereto. In addition, the number of extractions may be 1 to 5 times, but specifically, extraction may be repeated 3 times, but is not limited thereto. The extraction time may be 2 to 12 hours, specifically 3 to 5 hours, but is not limited thereto. In addition, after the extraction, a method such as concentration or freeze drying may be additionally performed.

According to an exemplary embodiment, it is possible to prepare a millet extract by a supercritical fluid extraction method by decompression by carbon dioxide and high temperature, and in general, a supercritical fluid is a liquid and gas obtained when a gas reaches a critical point under high temperature and high pressure conditions. Because of this characteristic, supercritical fluids are used for the extraction of oil-soluble substances because of the properties of and chemically similar polarity to non-polar solvents. Carbon dioxide becomes a supercritical fluid having both liquid and gaseous properties as the pressure and temperature reach a critical point due to the operation of the supercritical fluid device, and as a result, the solubility of the oil-soluble solute increases. When the supercritical carbon dioxide passes through an extraction container containing a certain amount of a sample, the fat-soluble material contained in the sample is extracted and released into the supercritical carbon dioxide. After extracting the fat-soluble substance, if the supercritical carbon dioxide containing a small amount of co-solvent flows through the sample remaining in the extraction container again, components that were not extracted with pure supercritical carbon dioxide can be extracted.These co-solvents are chloroform, ethanol, and One or a mixture of two or more selected from the group consisting of methanol, water, ethyl acetate, hexane, and diethyl ether may be used. Most of the extracted samples contain carbon dioxide, but carbon dioxide is volatilized into the air at room temperature, and the co-solvent can be removed with a vacuum evaporator.

According to an exemplary embodiment, it is possible to prepare the millet extract by an ultrasonic extraction method using energy generated by ultrasonic vibration. Ultrasonic waves can destroy insoluble substances contained in a sample in an aqueous solvent, and due to the high local temperature generated at this time, the kinetic energy of the reactant particles located around it increases, so that sufficient energy required for the reaction is obtained. By inducing a high pressure due to the impact effect of, the extraction efficiency increases by increasing the mixing effect of the material contained in the sample and the solvent.

의 통상적인 미생물 배양 조건으로 배양하고 pH는 5 내지 7로 호기적 또는 혐기적인 조건에서 약 5 내지 10일간 배양하며, 이후 숙성 및 여과를 통해 추출물을 얻을 수 있다.According to an exemplary embodiment, it is possible to manufacture the millet extract through a fermentation process. After the millet is finely crushed to about 100 to 500 mesh, a conventional microorganism culture solution is added at 1 to 50 g/L, and microorganisms such as yeast or lactic acid bacteria are added in an amount of 10,000 to 100,000 cfu/L. Incubation temperature is 30 to 37

It is cultured under conventional microbial culture conditions and the pH is 5 to 7 and cultured for about 5 to 10 days under aerobic or anaerobic conditions, and then the extract can be obtained through aging and filtering.

When the composition according to the present invention is applied to a pharmaceutical product, it can be formulated as an oral or parenteral administration in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier using the composition as an active ingredient.

The preparations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups, pellets, and the like. In addition, the preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, and suppositories. In order to formulate the active ingredient of the present invention, it can be easily formulated if carried out according to conventional methods, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, and other commonly used auxiliary agents can be appropriately used.

The pharmaceutical composition according to the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, and the like.

The active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Determination of the applied amount based on these factors is within the level of those skilled in the art, and its daily dose is, for example, 0.1 mg/kg/day to 100 mg/kg/day, more specifically 5 mg/kg/day to 50 mg/kg. /It can be work, but is not limited thereto.

Another aspect provides a food composition for preventing or improving liver fibrosis, comprising the extract of eyelets as an active ingredient.

The composition may be processed into a drink, fermented milk, cheese, yogurt, juice, probiotics, health supplements, etc., and may be used in the form of various other food additives.

In one embodiment, the composition may contain other ingredients that can give a synergistic effect to the main effect within a range that does not impair the main effect targeted by the present invention. For example, additives such as fragrances, coloring agents, disinfectants, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers, and synthetic polymer substances may be further included in order to improve physical properties. In addition, auxiliary ingredients such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, and seaweed extract may be further included. The above ingredients may be appropriately selected and blended by a person skilled in the art according to the formulation or purpose of use, and the amount added may be selected within a range not impairing the object and effect of the present invention.

The formulation of the composition according to the present invention may be in various forms such as solutions, emulsions, viscous mixtures, tablets, powders, etc., which may be administered by various methods such as simple drinking, injection administration, spray method, or squeeze method.

Hereinafter, an example of the formulation of the composition according to the present invention will be described, but the pharmaceutical composition and the cosmetic composition can be applied to various formulations, which are intended to be described only in detail, not to limit the present invention.

Formulation Example 1: Soft Capsule

150 mg of millet extract, 2 mg of palm oil, 8 mg of hydrogenated palm oil, 4 mg of sulfur wax, and 6 mg of lecithin were mixed, and 400 mg per capsule was filled according to a conventional method to prepare a soft capsule.

Formulation Example 2: Tablet

After mixing 150 mg of millet extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate, and adding 40 mg of 30% ethanol to form granules, dried at 60°C and purified using a tablet press It was tableted with.

Formulation Example 3: Granules

150 mg of millet extract, 100 mg of glucose, 50 mg of red ginseng extract, and 600 mg of starch were mixed to form granules, and 100 mg of 30% ethanol was added to form granules, followed by drying at 60°C to form granules, and then filled into a cloth. The final weight of the contents was 1 g.

Formulation Example 4: Drink

150 mg of millet extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled into a bottle. The final volume of the contents was 200 ml.

Formulation Example 5: Preparation of healthy food

Eyelashes extract ..............................1000 ㎎

Vitamin mixture

Vitamin A acetate............70 ㎍

Vitamin E ............................................1.0 mg

Vitamin B1........................................... 0.13 mg

Vitamin B2 ................................0.15 mg

Vitamin B6........................................... 0.5 mg

Vitamin B12......................................... 0.2 ㎍

Vitamin C............................................. 10 mg

Biotin...................................... 10 μg

Nicotinic acid amide..................................1.7 mg

Folic acid... ..... 50 ㎍

Calcium pantothenate............. 0.5 mg

Mineral mixture

Ferrous sulfate.......................................... 1.75 mg

Zinc oxide.............................................. 0.82 mg

Magnesium carbonate......................................25.3 mg

Potassium Phosphate Monobasic.........................................15 ㎎

Dicalcium Phosphate..........................................55 ㎎

Potassium citrate............................................90 mg

Calcium carbonate..............................................100 mg

Magnesium chloride.....................................24.8 mg

The composition ratio of the vitamin and mineral mixture is relatively suitable for health food, but it may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. , To prepare granules, and can be used to prepare a health food composition according to a conventional method.

Formulation Example 6: Preparation of healthy beverage

Millet extract............1000 mg

Citric acid................................................. .... 1000 mg

oligosaccharide................................................. .... 100 g

Plum Concentrate... ..... 2 g

Taurine............................ ........ 1 g

Total by adding purified water.........900 ml

After mixing the above ingredients according to a conventional health drink manufacturing method, stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 liter container, sealed and sterilized, and then stored in a refrigerator. It is used in the manufacture of health beverage composition.

The composition ratio is composed of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as the demand class, the country of demand, and the intended use. Those of ordinary skill in the art to which the present invention belongs will be able to perform various applications and modifications within the scope of the present invention based on the above contents.

As described above, specific parts of the present invention have been described in detail, and it is obvious that these specific techniques are only preferred embodiments for those of ordinary skill in the art, and the scope of the present invention is not limited thereby. something to do. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.

In the composition according to an aspect of the present invention, the active ingredient may reduce an inflammatory response induced by fatty liver in the liver.

In one aspect of the present invention, the active ingredient, millet extract, may reduce liver damage through alleviation of liver fibrosis.

In one aspect of the present invention, the active ingredient, millet extract may reduce liver fibrosis.

The composition of the present invention contains the millet extract as an active ingredient, can suppress the inflammatory reaction in the liver tissue, and can suppress liver damage, and is therefore useful for preventing, treating or improving liver fibrosis.

The composition of the present invention contains a natural extract, millet extract, as an active ingredient, and has an effect on the prevention and treatment of liver fibrosis as mentioned above, and has no side effects and excellent stability when applied to a living body.

FIG. 1 is a result of observing changes in liver tissue due to an extract of millet algae in mice in which steatohepatitis was induced by providing an MCD diet.
Figure 2 shows the effect of inhibiting ALT by the millet extract in mice induced with steatohepatitis by providing an MCD diet.
Figure 3 shows the AST inhibitory effect of the millet extract in mice induced steatohepatitis by providing an MCD diet.
Figure 4 shows the LDH inhibitory effect of the millet extract in mice induced with steatohepatitis by providing an MCD diet.
Figure 5 shows the effect of inhibiting MCP-1 expression by the millet extract in mice induced with steatohepatitis by providing an MCD diet.
Figure 6 shows the effect of inhibiting ICAM-1 expression by the millet extract in mice induced with steatohepatitis by providing an MCD diet.
Figure 7 is a microscopic observation of the effect of suppressing liver fibrosis by an extract of millet rice in mice induced with steatohepatitis by providing an MCD diet.
Figure 8 shows the effect of inhibiting liver fibrosis by the extract of millet oleracea in mice induced with steatohepatitis by providing an MCD diet.
Figure 9 shows the effect of inhibiting the expression of α-SMA in mice induced steatohepatitis by providing an MCD diet.
Figure 10 shows the effect of inhibiting the expression of COL1A1 by the millet extract in mice induced with steatohepatitis by providing an MCD diet.
Figure 11 shows the effect of inhibiting the expression of COL3A1 by the millet extract in mice induced with steatohepatitis by providing the MCD diet.

Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.

Preparation Example 1: Preparation of millet extract

The millet grass collected at Pyeongchang Wild Vegetable Test Center, Gangwon-do, was dried in the shade, cut into appropriate sizes, and extracted with ultrasonic waves by adding 1 kg of millet and 5 L of 70% ethanol to an extraction container, and filtered through filter paper to obtain an extract. The extraction process was repeated 3 times, and then the solvent was concentrated under reduced pressure and dried to obtain 70 g of an ethanol extract.

Example 1: Confirmation of changes in liver tissue of mice induced steatohepatitis by dietary MCD (methionine choline deficient) with millet extract

C57BL/6 db/db mice (male, 5 weeks old) were obtained from Jungang Animal Experiment Co., Ltd. and after an adaptation period for 1 week, they were divided into 5 test groups (n=6 per group) according to their weight. The experimental group provided MCD diet for 3 weeks to induce steatohepatitis, and the normal control group provided diet supplemented with methionine and choline (MCS). Dark: The light cycle was maintained at 12 hours: 12 hours intervals, and water was freely ingested. The diet, dosage, and administration method administered to the experimental group are shown in Table 1 below. The test substance was prepared in the form of a suspension liquid formulation using 0.5% CMC, and the test substance was administered for 3 weeks. To correct the placebo effect of 0.5% CMC and the effect of weight loss due to administration stress, 0.5% CMC was administered orally to the vehicle control group every day. As a result, as shown in Fig. 1, fatty liver was induced in the liver tissue, and it was confirmed that there was a change in liver tissue morphology in the mouse group fed the positive control GFT 505 and the millet extract compared to the group fed only the MCD diet.

Test group feed Test substance Dosage and method Administration period One MCS diet vehicle - 3 weeks 2 MCD diet vehicle - 3 MCD diet GFT 505 10 mg/kg, once a day 4 MCD diet Millet extract 100 mg/kg, once a day

Example 2: Confirmation of liver damage index of mice induced obesity by dietary MCD (methionine choline deficient) using millet extract

In Example 1, after completion of the administration of the millet extract for a total of 3 weeks, blood samples of all administration groups were taken to confirm the levels of ALT, AST, and LDH, which are representative liver damage indicators.

As a result, as shown in Figures 2 to 4, compared to the control group fed the MCS, the vehicle control group fed the MCD diet increased ALT, AST, and LDH levels, and it was confirmed that liver damage was promoted due to the induction of steatohepatitis. , It was confirmed that the level of liver damage index decreased through the administration of the millet extract.

Example 3: Confirmation of inhibition of inflammation-related mRNA expression in mice induced obesity with MCD (methionine choline deficient) diet by millet extract

After the end of administration of the millet extract for a total of 3 weeks in Example 1, the expression levels of inflammation-related mRNA in liver tissues of all administration groups were confirmed.

As a result, as shown in Figs. 5 and 6, it was confirmed that the expression of inflammation-related mRNA such as liver MCP-1 and ICAM-1 was rapidly increased in the vehicle control group provided with the MCD diet compared to the control group receiving the MCS diet. . In contrast, it was confirmed that the administration of millet extract lowered the expression of inflammation-related mRNA to the level of GFT, a positive control, reducing the inflammatory response of the liver.

Example 4: Confirmation of hepatic fibrosis inhibition in mice induced obesity with MCD (methionine choline deficient) diet by millet extract

In Example 1, after the administration of the millet extract for a total of 3 weeks, Sirius red staining was performed to stain fibrous tissue on liver tissue sections of all administration groups, and the level of liver fibrosis was confirmed by measuring the hydroxyl proline content of the liver tissue. . In addition, mRNA expression levels related to liver fibrosis such as -SMA, COL1A1, and COL3A1 were confirmed.

As a result, as shown in Figures 7 and 8, compared to the control group fed the MCS diet, the vehicle control group provided with the MCD diet confirmed that liver fibrosis progressed rapidly, and the experimental group fed the positive control GFT suppressed liver fibrosis. I couldn't see the effect. In contrast, it was confirmed that fibrosis of the liver was significantly suppressed through administration of the millet extract.

In addition, as shown in Figs. 9 to 11, compared to the control group fed with MCS diet, the administration of the millet extract compared to the increase in the mRNA expression level of α-SMA, COL1A1, COL3A1, etc. related to liver fibrosis in the vehicle control group provided with the MCD diet. It was confirmed that the mRNA expression level of related factors was suppressed.

Claims (6)

A pharmaceutical composition for the prevention or treatment of liver fibrosis, comprising an eyelashes extract as an active ingredient. A food composition for preventing or improving liver fibrosis, comprising an millet extract as an active ingredient. The composition according to claim 1 or 2, wherein the active ingredient reduces the inflammatory response in the liver. The composition according to claim 1 or 2, wherein the active ingredient reduces liver damage caused by fatty liver, steatohepatitis, cirrhosis or hepatic fibrosis. The composition according to claim 1 or 2, wherein the composition comprises 0.001 to 80% of the millet extract based on the total weight of the composition. A method for preventing or treating liver fibrosis, comprising administering the pharmaceutical composition of claim 1 to a mammal other than a human.

Images